Xia Yang

Xia YANG (Sophia) is a seasoned professional with extensive experience in the pharmaceutical and financial sectors. Since 2021, Xia YANG has been serving as the Director of Investor Relations at 基石药业, focusing on investor communication, valuation modeling, and strategic analysis. Previously, Xia YANG held key positions at prominent companies such as Bristol Myers Squibb, AstraZeneca, and Pfizer, where responsibilities included market analysis, oncology strategy formulation, and evaluation of business development opportunities. Early career roles at UBS and PwC involved participation in IPOs, asset restructuring, and financial auditing. Xia YANG possesses a Master's degree in Biochemistry and Molecular Biology from Peking University, obtained in 2011.